Supplementary Table 1.
Baseline characteristics of the analysis population used to evaluate tacrolimus trough concentrations and total daily dose.
| Characteristic | Rapid metabolizers | Intermediate metabolizers | Slow metabolizers | |||
|---|---|---|---|---|---|---|
| LCPT (n=68) | IR-Tac (n=72) | LCPT (n=70) | IR-Tac (n=74) | LCPT (n=68) | IR-Tac (n=72) | |
| Age (years), mean (SD) | 41.9 (13.34) | 43.2 (14.01) | 45.1 (13.20) | 45.4 (14.04) | 45.9 (14.27) | 49.0 (15.19) |
| Sex, n (%) | ||||||
| Male | 44 (64.7%) | 52 (72.2%) | 47 (67.1%) | 46 (62.2%) | 48 (70.6%) | 50 (69.4%) |
| Female | 24 (35.3%) | 20 (27.8%) | 23 (32.9%) | 28 (37.8%) | 20 (29.4%) | 22 (30.6%) |
| Race, n (%) | ||||||
| White | 46 (67.6%) | 49 (68.1%) | 55 (78.6%) | 60 (81.1%) | 51 (75.0%) | 55 (76.4%) |
| Black or African American | 6 (8.8%) | 6 (8.3%) | 0 | 3 (4.1%) | 1 (1.5%) | 3 (4.2%) |
| Asian | 3 (4.4%) | 4 (5.6%) | 4 (5.7%) | 2 (2.7%) | 1 (1.5%) | 3 (4.2%) |
| Other | 13 (19.1%) | 13 (18.1%) | 11 (15.7%) | 9 (12.2%) | 15 (22.1%) | 11 (15.3%) |
| Donor type, n (%) | ||||||
| Living | 35 (51.5%) | 31 (43.1%) | 37 (52.9%) | 33 (44.6%) | 34 (50.0%) | 37 (51.4%) |
| Deceased | 33 (48.5%) | 41 (56.9%) | 33 (47.1%) | 41 (55.4%) | 34 (50.0%) | 35 (48.6%) |
| Previous transplant, n (%) | 3 (4.4%) | 1 (1.4%) | 6 (8.6%) | 4 (5.4%) | 1 (1.5%) | 5 (6.9%) |
| Treatment duration (days), mean (SD) | 558.5 (265.88) | 630.9 (197.50) | 671.3 (156.58) | 647.9 (181.41) | 649.5 (177.00) | 629.8 (200.62) |
| C/D ratio*,** | <0.96 | <0.83 | 0.96–1.47 | 0.83–1.37 | >1.47 | >1.37 |
Analysis population consisted of patients who had a calculable day 30 C/D ratio based on central laboratory data only.
*
C/D ratio cutoffs differ between formulations because of inherent differences in bioavailability; LCPT has a higher bioavailability resulting in lower average doses;
**
Day 30 ratio of trough concentration obtained from central laboratory.
C/D – concentration/dose; IR-Tac – immediate-release tacrolimus; LCPT – LCP-tacrolimus; SD – standard deviation.